NATIONAL INSTITUTES OF HEALTH AWARDS GRANT TO SINTX TECHNOLOGIES FOR DEVELOPMENT OF 3D PRINTED ANTIMICROBIAL TRAUMA DEVICE
September 29 2022 - 9:00AM
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or
the “Company”), an original equipment manufacturer (OEM) of
advanced ceramic materials for medical and technical applications,
announced today a Phase I grant of $275k awarded by the National
Institutes of Health (NIH) to develop and test an antimicrobial
trauma device. The device will be constructed of a 3D printed
continuous carbon fiber (cCF) reinforced polyetherketoneketone
(PEKK) plate with silicon nitride embedded into its surface. The
Phase I grant represents the third grant awarded to SINTX by the
NIH in the past year.
SINTX will collaborate with Drexel University,
Thomas Jefferson University, and the University of Pennsylvania
over the coming twelve months to develop and test this novel
infection-resistant trauma plate. The trauma plate will also
feature design customization through the 3D printing production
method. The composite material forming the device will feature the
improved fatigue properties, imaging characteristics, and tailored
stiffness of cCF-PEKK with improved biocompatibility and
antibacterial properties from silicon nitride.
“Orthopedic trauma procedures can unfortunately
have some of the highest infection rates of all surgical
specialties. So, the need for antibacterial material
characteristics, especially in this area of orthopedic surgery, is
tremendous,” said Dr. Ryan Bock, Vice President of Research &
Development, SINTX Technologies. “We believe that a 3D printed
trauma plate which features silicon nitride embedded into the
cCF-PEKK material could potentially be a game changer for ortho
trauma. We’re excited about the possibilities and ready to begin
this work under our Phase I NIH grant.”
Orthopedic trauma plates are implantable devices
used to repair bone fractures. Current materials used in this
application, primarily metals, provide little protection against
infection, which can occur at rates as high as 30% in cases where
open site fixation is required. The SINTX grant funds, issued under
award 1R41AR082266-01, will be used to design and develop a trauma
plate that meets or exceeds established mechanical performance
requirements and demonstrates strong antibacterial activity.
Successful completion of this effort will position SINTX to apply
for a Phase II award to support commercialization of the
technology.
For more information, please visit https://sintx.com/.
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics
company that develops and commercializes materials, components, and
technologies for medical and technical applications. SINTX is a
global leader in the research, development, and manufacturing of
silicon nitride, and its products have been implanted in humans
since 2008. Over the past two years, SINTX has utilized strategic
acquisitions and alliances to enter into new markets. The Company
has manufacturing facilities in Utah and Maryland.
Forward-Looking Statements for SINTX Technologies,
Inc.
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA), including those relating to development
of a 3D printed trauma plate that meets or exceeds established
mechanical performance requirements and demonstrates strong
antibacterial activity, and the ability of SINTX to apply for a
Phase II award. Such forward-looking statements are subject to a
number of risks and uncertainties. Risks and uncertainties that may
cause such differences include, among other things: unforeseen
difficulties in designing and developing an antimicrobial trauma
device, our products may not prove to be as effective as other
products currently being commercialized or to be commercialized in
the future by competitors; risks inherent in manufacturing and
scaling up to commercial quantities while maintaining quality
controls; volatility in the price of SINTX’s common stock; the
uncertainties inherent in new product development, including the
cost and time required to commercialize such product(s); market
acceptance of our products once commercialized; SINTX’s ability to
raise funding and other competitive developments. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management’s current estimates, projections,
expectations, and beliefs. There can be no assurance that any of
the anticipated results will occur on a timely basis or at all due
to certain risks and uncertainties, a discussion of which can be
found in SINTX’s Risk Factors disclosure in its Annual Report on
Form 10-K, filed with the Securities and Exchange Commission (SEC)
on March 25, 2022, and in SINTX’s other filings with the SEC. SINTX
undertakes no obligation to publicly revise or update the
forward-looking statements to reflect events or circumstances that
arise after the date of this report.
Business or Media
Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Mar 2024 to Apr 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Apr 2023 to Apr 2024